91816-25-0

Downstream Products

• 4458-08-6 4-(N-methyl-p-methylphenylhydrazono)-3-phenylisoxazol-5-one 
• 98664-25-6 2-methyl-3-phenyl-4-(p-methylphenylazo)isoxazol-5-one 
• 91816-24-9 3-Phenyl-4-(p-tolyl-hydrazono)-4H-isoxazole-5-thione 
• 91816-07-8 3-{[3-Phenyl-4-(p-tolyl-hydrazono)-4H-isoxazol-(5Z)-ylidene]-hydrazono}-butyric acid ethyl ester 
• 91816-18-1 1-Phenyl-2-(3-phenyl-4-p-tolylazo-isoxazol-5-ylsulfanyl)-ethanone 
• 91816-20-5 (3-Phenyl-4-p-tolylazo-isoxazol-5-ylsulfanyl)-acetic acid ethyl ester 
• 91816-05-6 N-[3-Phenyl-5-{[1-phenyl-meth-(E)-ylidene]-hydrazono}-isoxazol-(4E)-ylidene]-N'-p-tolyl-hydrazine 
• 91816-09-0 C₂₂H₁₉N₅O 
• 91816-11-4 3-Oxo-3-phenyl-2-(p-tolyl-hydrazono)-propionic acid N'-phenyl-hydrazide 
• 91816-22-7 2-(3-Phenyl-4-p-tolylazo-isoxazol-5-ylsulfanyl)-acetamide 
• 91816-03-4 N-[5-Hydrazono-3-phenyl-isoxazol-(4E)-ylidene]-N'-p-tolyl-hydrazine 
• 91816-15-8 4-(Methyl-p-tolyl-hydrazono)-3-phenyl-4H-isoxazole-5-thione 
• 91816-13-6 (5-Methylsulfanyl-3-phenyl-isoxazol-4-yl)-p-tolyl-diazene 
• 91816-16-9 5-Phenyl-2-p-tolyl-2H-[1,2,3]triazole-4-carbothioic acid S-methyl ester 

Relevant academic research and scientific papers

Synthesis and biological evaluation of polyfluoroalkyl-containing 4-arylhydrazinylidene-isoxazoles as antifungal agents with antioxidant activity

The regioselective cyclization of 2-arylhydrazinylidene-3-polyfluoroalkyl-3-oxo esters with hydroxylamine resulted in 4-arylhydrazinylidene-3-polyfluoroalkylisoxazol-5-ones, while the analogous reaction of 2-arylhydrazinylidene-3-polyfluoroalkyl-1,3-diketones led to 4-arylhydrazinylidene-5-polyfluoroalkyldihydroisoxazol-5-oles, which were dehydrated to 4-arylhydrazinylidene-5-polyfluoroalkylisoxazoles. To explain a regioselectivity of reactions, the quantum-chemical calculations were performed. The structure of the synthesized compounds was confirmed by IR, NMR spectroscopy, mass spectrometry, elemental analysis and X-Ray diffraction analysis. Almost all isoxazolones and dihydroisoxazoles demonstrated an inhibitory action against the majority of investigated strains of dermatophytes Trichophyton family, E. floccosum, and M. canis, while isoxazoles were found to be inactive. The lead compounds were 4-tolylhydrazinylidene-3-trifluoromethylisoxazol-5-one, 3-methyl-5-pentafluoroethyl- and 3-phenyl-5-trifluoromethyl-4-tolylhydrazinylidenedihydroisoxazol-5-oles having the antifungal activity against all dermatophyte strains (MIC 0.78…25 μg/kg) and C. ablicans yeasts (MIC 25 μg/kg). Seven derivatives showed a moderate antibacterial activity against N. gonorrhoeae (MIC 31.2…62.5 μg/kg). In addition, dihydroisoxazololes demonstrated a high antioxidant activity in the ABTS (TEAC is up to 2.0) and FRAP (TE is up to 1.91) tests, which could be helpful for hepatotoxicity reducing. The results obtained show the absence of anticholinesterase activity in all the compounds and demonstrate a weak inhibition of CES by most of the compounds, that should be taken into consideration in the therapeutic use of the compounds in high doses.